[Management of spasticity in children with cerebral palsy]

Acta Orthop Traumatol Turc. 2009 Mar-Apr;43(2):81-6. doi: 10.3944/AOTT.2009.081.
[Article in Turkish]

Abstract

Management of spasticity is a major challenge to the rehabilitation team. The initial management has centered on the elimination of externally exacerbating causes, physical therapy, splinting and casting. Medical management has centered on anti-spasticity medication use, but more recently focal treatment methods including phenol blocks and botulinum toxin have been utilized. There has been an increased use of intrathecal baclofen in the management of refractory tone. Dorsal rhizotomy has been advocated for a selective population of children with spasticity. There is no standardized approach to spasticity management and this paper will discuss the importance of evidence-based treatment of spasticity that is adapted for the individual child.

Publication types

  • English Abstract

MeSH terms

  • Administration, Oral
  • Anti-Dyskinesia Agents
  • Baclofen / administration & dosage
  • Baclofen / therapeutic use
  • Benzodiazepines / administration & dosage
  • Benzodiazepines / therapeutic use
  • Botulinum Toxins
  • Cerebral Palsy / physiopathology
  • Cerebral Palsy / therapy*
  • Child
  • Dantrolene / administration & dosage
  • Dantrolene / therapeutic use
  • Evidence-Based Medicine / methods*
  • GABA Agonists / administration & dosage
  • GABA Agonists / therapeutic use
  • Humans
  • Injections, Spinal
  • Muscle Relaxants, Central / administration & dosage
  • Muscle Relaxants, Central / therapeutic use
  • Muscle Spasticity / drug therapy
  • Muscle Spasticity / rehabilitation
  • Muscle Spasticity / surgery
  • Patient-Centered Care / methods
  • Phenol
  • Rhizotomy
  • Sympathectomy, Chemical / methods

Substances

  • Anti-Dyskinesia Agents
  • GABA Agonists
  • Muscle Relaxants, Central
  • Benzodiazepines
  • Phenol
  • Botulinum Toxins
  • Dantrolene
  • Baclofen